Editorial
Tri-modality treatment in N2 stage IIIa non-small cell lung cancer: proper sequence remains unknown
Abstract
Pathologic stage IIIA non-small cell lung cancer (NSCLC) is a challenging disease to treat and the role of postoperative radiotherapy (PORT) in patients following resection remains controversial.
